Exclusive Summary

• Specifically targeted at the US market, strategically positioned to capitalize on patent cliffs or shortage windows with high commercial potential.
• Adopts a Flexible NewCo partnership model, ensuring clear asset ownership and facilitating risk segregation and capital operation for overseas partners.
• Leverages China's mature supply chain to deliver significant cost advantages (COGS) and competitive profit margins while maintaining FDA-compliant quality.
• Product positioning aligns with US FDA regulatory requirements and clinical substitution standards, serving as a cost-effective alternative to the RLD.

Asset Materials

Contact Us for Full Materials